Hyundai Bioscience Co., Ltd.
June 16, 2025
Company Presentation
Other
Hyundai Bioscience is a biotech company in South Korea dedicated to therapeutic solutions for infectious diseases and cancer. We repurpose and expand indications of existing drugs using our novel DDS technologies. Our cancer portfolio includes POLYTAXEL® (Phase 1 IND for pancreatic cancer), a ‘pain-free’ injectable chemotherapy agent with low toxicity and tumor-targeting property; CSC-X™ (Phase 1/2 INDs for prostate cancer and solid tumors; Phase 1/2a IIT for leukemia with GFM), an oral drug targeting cancer stem cells; and OTX-M™, a metronomic chemotherapy solution utilizing an oral taxane formulation for low-dose, frequent treatment. Our broad-spectrum antiviral, XAFTY®, is in Phase 3 trial for COVID-19 in South Korea and Phase 2/3 for dengue in Vietnam. Clinical development efforts for Long COVID (IIT with UCSD) and mpox (with INRB and NDUTH) are ongoing, alongside preclinical studies targeting other viruses. We seek global partners to advance solutions and expand indications.
Company HQ City:
Gangseo-gu, Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2000
Lead Product in Development:
- Anticancer: POLYTAXEL®, CSC-X™, OTX-M™
- Antiviral: XAFTY®
CEO
Sang-Ki Oh
Year Founded
2000
Development Phase of Lead Product
Phase III
Exchange
KOSDAQ
Ticker
048410
When you expect your next catalyst update?
Progress of POLYTAXEL® clinical trial in Korea, and XAFTY®; dengue clinical trial in Vietnam, mpox clinical trial IND in DRC & Nigeria, and (possibly) RSV, hMPV, HAdV, mpox preclinical studies with NIH/NIAID
What is your next catalyst (value inflection) update?
2025 through early 2026
Website
http://www.hyundaibioscience.com/eindex.php
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}